How you can stay healthy when travelling overseas and what to do if you get sick
New COVID-19 subvariants are circulating across popular holiday destinations in South-East Asia, prompting health alerts and increased screening and surveillance measures in some ports.
While there are no new travel warnings specifically for Australians, doctors say now is the time to check vaccinations, pack health essentials, and take basic precautions like mask-wearing in crowded areas.
Here's what's happening in the region — and how you can stay healthy overseas, regardless of where you're travelling.
More than 236,000 COVID infections have been reported across South-East Asia in the past few weeks, according to the World Health Organization (WHO).
That includes more than 85,000 in Thailand and over 5,000 in India in the past week. The WHO says a new subvariant, NB.1.8.1, is driving an increase in cases in parts of South-East Asia and the Western Pacific.
The organisation is urging countries in the region to strengthen surveillance and encourage vaccinations.
In Bangladesh, authorities have urged citizens to avoid non-essential trips to India, Singapore, Thailand, Malaysia and Indonesia due to a sudden rise in COVID cases in those places.
The country has also bolstered health screening and surveillance measures at land, sea and air ports.
Professor Paul Griffin, an infectious diseases expert at the University of Queensland, says Australians should be aware of the spread of new subvariants.
"The risk of COVID is still significant — both while travelling and here in Australia," Professor Griffin says.
"The backbone of protection, whether at home or overseas, is vaccination and we're simply not doing enough of that at the moment."
Professor Griffin says the wave of new infections is linked to the FLiRT subvariant family and the newer NB.1.8.1 strain.
"It's not necessarily more severe, but it does seem better at evading previous immunity and attaching to human cells, making it more infectious," he says.
"That's why it's important to have a recent booster, like the JN.1-based one, which still offers excellent protection against these new strains."
Australia's Department of Foreign Affairs and Trade (DFAT) has not issued any new travel alerts specifically for COVID risk in South-East Asia.
However, it has advised to exercise a "high degree of caution" in Indonesia overall due to security risks.
The Australian government recommends you monitor Smartraveller for destination-specific health advice and stay informed about local rules and entry requirements.
Broadly, there are no signs Australians are reconsidering travel.
Source: ATIA, ABS
Demand for international flights remains high, with a new report from the Australian Travel Industry Association (ATIA) showing outbound travel up 12.1 per cent in the 12 months to April.
ATIA chief executive Dean Long says Australians are prioritising value and climate while COVID "is not really part of the decision-making process for most people".
"People who are worried are still taking precautions, but it's no longer top of mind for the majority of travellers."
Okay, but what if you're planning to travel elsewhere internationally?
Professor Griffin says healthy, vaccinated Australians can still travel safely but need to factor COVID into their planning.
"There are still basic things everyone can do: get a booster, wear a mask when appropriate, practice good hand hygiene and make sure you're in well-ventilated spaces," he says.
Professor Griffin says older Australians or those with pre-existing health conditions should consider getting tailored medical advice before they leave.
He recommended making sure vaccinations are up to date at least two weeks before departure.
Doctors say the best defence is preparation.
Pack a basic travel health kit, including hand sanitiser, masks, electrolytes, paracetamol and any personal medications.
If you do fall ill overseas, DFAT advises seeking local medical care promptly and contacting your travel insurer early, as they may help organise treatment or cover costs.
If you're too sick or need help finding an English-speaking doctor, DFAT can provide a list of nearby doctors or hospitals.
Consular officials can help connect you with local healthcare and provide support in emergencies.
Experts say yes, but only if you read the fine print.
Professor Griffin reiterated the importance of carefully reviewing travel insurance policies before departure.
"One of the big issues is coverage for pre-existing conditions," he says. "If your illness is deemed related to one of those, you may not be covered — even for COVID."
He also warned some insurers have scaled back the extra COVID protections they introduced during the pandemic, so you could be caught out if you need to cancel or extend your trip due to illness.
"If you get sick, you may need to isolate or delay your return. That's where good travel insurance really becomes critical."
Mr Long urged Australians to go beyond the basics for travel insurance, warning that some credit card policies offer limited protection.
"There are a number of policies that now include COVID because it's just a health condition," he says.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
3 hours ago
- News.com.au
‘Dark spots': COVID jab tied to rare health symptom
New research is calling for further study on a possible link between COVID-19 jabs and long-term vision issues. While vaccines have been vital in fighting the pandemic, emerging data could mean we're not out of the woods yet. Between January 2021 and January 2023, 20 peer-reviewed studies looked into eye problems reported by 243 people aged 18 to 84 who had received COVID-19 vaccines. Almost half of these patients - 42 per cent - had the Pfizer-BioNTech jab, which was the main vaccine rolled out in Australia, the USA, the UK, and much of Europe. What jumps out is inflammation. Nearly half of the patients reported experiencing ocular inflammatory conditions like uveitis, an irritation deep inside the eye. Another 24 per cent were said to have suffered optic neuritis, a swelling of the optic nerve that can cause pain and threaten vision. Herpetic eye disease, caused by the herpes virus attacking the eye, showed up in 14 per cent of cases, triggering redness, pain, and discomfort. About 10 per cent documented retinal circulation issues - blockages in the eye's arteries or veins that can trigger sudden vision loss. And there were also a few rare cases where patients were noted to exhibit retina-related problems causing 'dark spots' or 'blind patches'. But the most notable observations come from a recent Turkish study that tracked 64 patients before and after their two mRNA vaccine doses. Using detailed eye scans, researchers found an 8 per cent drop in the cornea's endothelial cell count - the cells responsible for keeping the cornea clear. These cells don't regenerate, and losing too many can permanently impair vision. To put that into perspective, healthy adults usually have between 2000 and 3000 of these cells per square millimetre. After vaccination, the average dropped from 2597 to 2378. While these numbers are still considered safe for most, the decline could be a warning sign for people with pre-existing eye conditions or those who have had eye surgeries like LASIK, cataract removal, or corneal transplants. Researchers also noted that corneas thickened by around 2 per cent after vaccination - a sign of possible swelling. The honeycomb shape of the endothelial cells became distorted, and the size differences between individual cells increased, which are both signs of cellular stress. Though none of the study participants reported immediate vision problems, experts warn that long-term structural changes to the cornea could lead to lasting damage, especially in vulnerable patients. Dr Fatma Sümer and Sevgi SubaÅŸi, authors of the study published in Ophthalmic Epidemiology, stressed the need for careful observation: 'The endothelium should be closely monitored in those with a low endothelial count or who have had a corneal graft.' According to Healthline, eye complications after vaccination are rare and appear to be driven by an overactive immune response. Symptoms can include blurred vision, light sensitivity, redness, eye pain, shingles around the eye, or reactivated herpes infections. In even rarer cases, the immune system may reject a previously transplanted cornea, risking vision loss and graft failure. This means the transplanted cornea loses its clarity and function, leading to impaired vision and the potential need for further treatment or surgery. These findings are not conclusive, and experts do not advise people to skip their COVID vaccine shots — far from it. But they are urging doctors and patients to not ignore these subtle warning signs. Those who have had prior eye surgery, suffer from chronic eye disease, or notice persistent blurry vision after vaccination are advised to be checked, because even small changes inside your eyes can have big consequences down the road According to safety reports from the Therapeutic Goods Administration (TGA), 'vaccination is the most effective way to reduce deaths and severe illness from infection.' Like all medicines, the TGA notes, 'COVID-19 vaccines may cause some side effects. 'The most frequently reported include injection-site reactions (such as a sore arm) and more general symptoms, like headache, muscle pain, fever and chills.' The TGA closely monitors reports of adverse events to the COVID-19 vaccines and emphasises that 'the protective benefits of vaccination far outweigh the potential risks.'
Sydney Morning Herald
7 hours ago
- Sydney Morning Herald
Ozempic drugmaker just became a victim of its own success
It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to potentially eradicate the insidious plague of obesity and address diabetes can be failing to meet its profit and sales expectations. But that is the dilemma faced by Ozempic and Wegovy maker Novo Nordisk. Its share price is shedding value faster than patients are shedding kilos. For blame, one need look no further than pirates and the president (Trump, of course). Novo Nordisk stunned investors on Wednesday by downgrading its earnings expectations, losing nearly a third of its share price at one point during the day's trading – that's $143 billion in value that evaporated in a couple of hours. For some context: there are plenty of spectacular drugs and treatments that have been developed over recent decades to address many of the world's serious health issues, from cancer to heart disease, but this drug tackles obesity and therefore the myriad other health conditions that stem from being overweight (such as stroke, osteoarthritis, heart disease and even some cancers). As such, it is a game-changer. These semaglutide drugs became so popular after their efficacy for weight loss became apparent that in a sense they became victims of their own success. According to the World Health Organisation, about one billion people around the globe are obese, which means the addressable market for this drug is beyond huge and skewed to Western (and therefore wealthier) economies. And that market is still growing. The number of people afflicted by obesity has doubled over the past 30 years in adults, and quadrupled in children and adolescents, the WHO says.
The Age
7 hours ago
- The Age
Ozempic drugmaker just became a victim of its own success
It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to potentially eradicate the insidious plague of obesity and address diabetes can be failing to meet its profit and sales expectations. But that is the dilemma faced by Ozempic and Wegovy maker Novo Nordisk. Its share price is shedding value faster than patients are shedding kilos. For blame, one need look no further than pirates and the president (Trump, of course). Novo Nordisk stunned investors on Wednesday by downgrading its earnings expectations, losing nearly a third of its share price at one point during the day's trading – that's $143 billion in value that evaporated in a couple of hours. For some context: there are plenty of spectacular drugs and treatments that have been developed over recent decades to address many of the world's serious health issues, from cancer to heart disease, but this drug tackles obesity and therefore the myriad other health conditions that stem from being overweight (such as stroke, osteoarthritis, heart disease and even some cancers). As such, it is a game-changer. These semaglutide drugs became so popular after their efficacy for weight loss became apparent that in a sense they became victims of their own success. According to the World Health Organisation, about one billion people around the globe are obese, which means the addressable market for this drug is beyond huge and skewed to Western (and therefore wealthier) economies. And that market is still growing. The number of people afflicted by obesity has doubled over the past 30 years in adults, and quadrupled in children and adolescents, the WHO says.
